St Helena receives FCDO funds for healthcare equipment upgrade

Nigel Phillips CBE, Governor of St Helena, Ascension and Tristan da Cunha
Nigel Phillips CBE, Governor of St Helena, Ascension and Tristan da Cunha | Twitter Website

In November 2022, St Helena was earmarked to receive funding from the Foreign, Commonwealth and Development Office’s (FCDO) Improving Essential Equipment in Overseas Territories Programme for 2022/2023. The island was allocated up to £1,800,000 for acquiring critical equipment across several sectors including healthcare, emergency services, port operations, road maintenance, and airport operations.

The Health and Social Care Portfolio received a total of £797,159.48 from this allocation. This amount was utilized to procure various medical tools such as cardiac equipment, biochemistry analyser, haematology analyser, haemoglobin A1c analyser, FibroScan 530 Compact and M probe, immunoassay analyser, blood culture analyser, CT scanner (including servicing contract), and portable ultrasound machine. These installations are expected to enhance on-island illness management and minimize off-island referrals by improving assessment turnaround times and patient care delivery.

An expenditure of £138,600.74 went towards acquiring a cardiac stress test system along with electrocardiogram (ECG) machines and Heartstart Intrepid Defibrillators aimed at early heart disease detection and emergency lifesaving interventions.

A sum of £53,512.13 was used for purchasing a biochemistry analyser alongside a haematology analyser. These upgrades replaced outdated equipment nearing the end of their functional lifespan.

For diagnosing and monitoring diabetes patients amidst rising demand for tests on the island, a Hemoglobin A1C analyser costing £27,429.40 was procured to replace an older model.

£82,089.96 facilitated the acquisition of a FibroScan 530 Compact with an M probe to assist health staff in detecting liver disease—an element crucial to the Health Directorate’s strategy against obesity-related conditions.

The immunoassay analyser purchased for £46,751.30 will expand testing capabilities locally while reducing overseas test dependencies; thereby optimizing result turnaround times and costs.

To detect sepsis early on in patients—a task previously requiring up to 72 hours manually—a blood culture analyser worth £24,909.88 has been installed that delivers results within 10-12 hours post-onset.

A substantial investment of £423,866.07 secured both a CT scanner capable of advanced imaging tasks like coronary artery assessments and bone mineral density scans due its sophisticated features including artefact reduction technology; plus portable ultrasound equipment enhancing point-of-care diagnostics efficiency through mobility advantages during patient assessments or emergencies.




Top